These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 38153656)

  • 21. Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles.
    Petrilli R; Pinheiro DP; de Cássia Evangelista de Oliveira F; Galvão GF; Marques LGA; Lopez RFV; Pessoa C; Eloy JO
    Curr Med Chem; 2021; 28(13):2485-2520. PubMed ID: 32484100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
    Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
    Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies and challenges for the next generation of antibody-drug conjugates.
    Beck A; Goetsch L; Dumontet C; Corvaïa N
    Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G
    Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the next generation of antibody-drug conjugates.
    Tsuchikama K; Anami Y; Ha SYY; Yamazaki CM
    Nat Rev Clin Oncol; 2024 Mar; 21(3):203-223. PubMed ID: 38191923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-Drug Conjugates-Evolution and Perspectives.
    Chis AA; Dobrea CM; Arseniu AM; Frum A; Rus LL; Cormos G; Georgescu C; Morgovan C; Butuca A; Gligor FG; Vonica-Tincu AL
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates come of age in oncology.
    Dumontet C; Reichert JM; Senter PD; Lambert JM; Beck A
    Nat Rev Drug Discov; 2023 Aug; 22(8):641-661. PubMed ID: 37308581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for oncology?
    Begum SA; Kamal A
    Expert Opin Drug Discov; 2023 Jun; 18(6):591-596. PubMed ID: 37089024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.
    Gauzy-Lazo L; Sassoon I; Brun MP
    SLAS Discov; 2020 Sep; 25(8):843-868. PubMed ID: 32192384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Picking the optimal target for antibody-drug conjugates.
    Mathur R; Weiner GJ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.
    Li WQ; Guo HF; Li LY; Zhang YF; Cui JW
    Cancer Med; 2021 Jul; 10(14):4677-4696. PubMed ID: 34165267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
    Takakura T; Shimizu T; Yamamoto N
    Jpn J Clin Oncol; 2024 Aug; 54(8):837-846. PubMed ID: 38704241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.
    Medina Pérez VM; Baselga M; Schuhmacher AJ
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity.
    Dong W; Wang W; Cao C
    ChemMedChem; 2024 Sep; 19(17):e202400109. PubMed ID: 38758596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.
    He J; Zeng X; Wang C; Wang E; Li Y
    MedComm (2020); 2024 Aug; 5(8):e671. PubMed ID: 39070179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.